Sapience Therapeutics to Present at the 2019 Life Sciences Summit

HARRISON, NY / ACCESSWIRE / October 29, 2019 / –Sapience Therapeutics, Inc., a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications, announced today that it is scheduled to present and participate in a panel discussion at the Life Sciences Summit to be held in New York, NY from Nov 6 – Nov 7, 2019.

Barry Kappel, PhD., MBA, President and Chief Executive Officer, will present an overview of the company’s platform, pipeline, and lead candidate ST101. Dr. Kappel will also be participating in a panel discussion following the presentation.

Details for the presentation are as follows:

Event: Life Sciences Summit
Date: Wednesday November 6, 2019
Time: 2:00 PM
Location: Convene 730 3rd Ave
Room: Soho Hub

Details for the panel discussion are as follows:

Session Title: Business Workshop: Preparing for Due Diligence
Date: Wednesday, November 6, 2019
Time: 3:30 PM – 4:25 PM

About Sapience Therapeutics

Sapience Therapeutics, Inc., is a privately held, preclinical biotechnology company focused on discovering and developing peptide-based therapeutics for major unmet medical needs, particularly high mortality cancers. With platform-based discovery of peptide therapeutics that disrupt protein-protein interactions, Sapience’s molecules hold potential to target intracellular interactions that are traditionally considered “undruggable targets”. Its lead compound, ST101, is a first-in-class molecule with potential applications in various solid tumors and hematologic malignancies. In 2016, Sapience Therapeutics closed its Series A financing, which was led by Eshelman Ventures and included investments from Celgene Corporation, TaiAn Technologies Corporation and Healthlink Capital. For more information on Sapience Therapeutics, please visit

Forward-Looking Statements

This press release contains forward-looking statements, and any statements other than statements of historical fact could be deemed to be forward-looking statements. These forward-looking statements may include, among other things, statements regarding future events that involve significant risks and uncertainties. These statements are based on management’s current expectations, and actual results and future events may differ materially as a result of certain factors, including, without limitation, risks related to the application of the net proceeds from the offering to Sapience’s product development objectives, our ability to obtain additional funds, and meet applicable regulatory standards and receive required regulatory approvals. These are forward-looking statements, which speak only as of the date of this press release. Sapience does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.


Sapience Therapeutics, Inc.:
Barry Kappel
President and Chief Executive Officer

SOURCE: Sapience Therapeutics, Inc.

View source version on

Released October 29, 2019